Ö÷²¥ÓÕ»ó

Object moved to here.

Ö÷²¥ÓÕ»ó :: Pilot & Feasibility Program Application

Ö÷²¥ÓÕ»ó


Hyperglycemia and white blood cell biology
Summary Data Summary
Applicant Goldberg, Ira
E-Mail Address ira.goldberg@nyumc.org
Project Title Hyperglycemia and white blood cell biology
CBU ID 11GHSU147
External SubContract ID 24958-4
Diabetic Complication Cardiovascular
Funding Program Group Pilot & Feasibility [PF2011]
Abstract Several complications of diabetes may be exacerbated by inflammation. Whether
this is due to hyperglycemia, defective insulin actions, or other metabolic
alterations of diabetes is unknown. In addition, both local tissue inflammation
and changes in the biology of circulating white blood cells (WBCs) could lead to
pathological changes in organs and vascular tissues. In this regard, we have
recently found that loss of WBCs from atherosclerotic mouse lesions is defective
in the presence of streptozotocin diabetes. Moreover, we provide Preliminary
Results showing that changes in circulating WBCs that occur with diabetes are
corrected by glucose reduction using inhibitors to the sodium glucose
co-transporter 2 (SGLT2). Thus, the studies proposed will allow us to
“understand the possible in vivo efficacy of a promising new therapy for
diabetesâ€, glucose reduction via inhibition of SGLT2. This Pilot application has
two aims: Aim 1. To determine if hyperglycemia reduction leads to an alteration
in the inflammatory state of circulating monocytes and neutrophils. Aim 2. To
determine whether glucose reduction in STZ-treated LDL receptor knockout mice
with atherosclerosis will reduce the inflammatory profile of lesional CD68+
cells. Techniques to lower glucose in diabetic mice, isolate circulating
monocytes subsets (Lys6-C hi and lo) and granulocytes by FACS, and vascular wall
CD68+ cells by laser capture microdissection are in hand. We expect that our
studies will clarify the importance of hyperglycemia alone in altering the
inflammatory status of circulating and vascular WBCs.
Application PDF Application Research Plan
Status Contract Executed
Key Personnel
Salary Total Costs 23573
Supply Total Costs 14000
Equipment Total Costs 0
Travel/Other Total Costs 24927
Direct Costs 62500
Indirect Costs Proposed 37500
Total Costs Proposed 100000
Total Costs Approved 100000
Start Date 9/1/2011
End Date 8/31/2012
IFO Name Berger, William
IFO E-Mail Address grants-office@columbia.edu
IACUC/IRB No. A3007-01
IACUC/IRB Institution Columbia University
Entity ID No. 135598093A7
Report Request Date 10/1/2012
T1D NO
TypeCount
Invoices 1
Progress Reports 1
Experiments 1
Data Submission


Invoices
UrlCBU IDExternal IDInstitutionDateDirectIndirectInvoiceBalancePDF
  View  11GHSU14724958-4Columbia University11/21/2012$25,675.82$15,405.49$41,081.31$58,918.69View PDF


Reports


Experiments
Click here to cancel and return to funding program application

*Author:
*SubContract:
*Select File:

Click browse and select the file to upload.
(Please upload ONLY TXT, Image Files (not histolgy), PDF, XLS, XLSX, DOC, or DOCX files.)